Señales en vivo de ANNX | Maximiza tus Ganancias con Getagraph.com

COMPRAR 140017 min ago

@ $5.26

Emitido: 14 feb 2024 @ 14:48

Retorno: -8.66%

Señal anterior: feb 14 - 09:31

Señal anterior: Vender

Retorno: 2.24 %

Live Chart Being Loaded With Signals

Commentary (21 may 2024 @ 16:00):

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders...

Stats
Volumen de hoy	946 984
Volumen promedio	1.93M
Capitalización de mercado	437.48M
EPS	$0 ( 2024-05-13 )
Próxima fecha de ganancias	( $-0.250 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.29
ATR14	$0.0100 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Carson William H.	Buy	3 200	Common Stock
2024-04-08	Carson William H.	Buy	3 200	Common Stock
2024-02-16	Love Douglas	Buy	656 200	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	160 000	Stock Option (Right to Buy)
2024-02-16	Dananberg Jamie	Buy	39 000	Common Stock

INSIDER POWER
80.75
Last 94 transactions
Buy: 9 091 580 \| Sell: 849 119

Volumen Correlación

Largo: 0.66 (moderate)

Corto: 0.71 (moderate)

Signal:(81.7) Neutral

Annexon, Inc. Correlación

10 Correlaciones Más Positivas
HNST	0.825
VINC	0.809

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Annexon, Inc. Correlación - Moneda/Commodity

-0.52
( weak negative )

0.34
( neutral )

0.00
( neutral )

0.22
( neutral )

-0.46
( neutral )

0.62
( weak )

Annexon, Inc. Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-3.27M (0.00 %)
EPS:	$-1.770

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-3.27M (0.00 %)
EPS:	$-1.770

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-3.31M (0.00 %)
EPS:	$-2.53

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-7.68

Financial Reports:

No articles found.

Annexon, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Annexon, Inc.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.